Lorlatinib Medication Guide Brief Description

Lorlatinib (Lorlatinib, also known as lorlatinib), is an advanced targeted therapy for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). This drug can effectively prevent the abnormal growth and spread of tumor cells by precisely inhibiting the activity of ALK receptor tyrosine kinase, opening a new treatment chapter for patients. It is particularly suitable for patients whose disease still progresses after treatment with crizotinib and at least one other ALK inhibitor, or whose disease is not controlled after treatment with alectinib or ceritinib as the first choice. It can also be used as a first-line treatment option for ALK-positive NSCLC.

Lorlatinib is available as an oral tablet for daily use. The recommended dose is 100 mg once a day, with or without food, and should be continued until the disease progresses or intolerable toxicity occurs. When taking, the tablets should be swallowed whole and should not be chewed, crushed or divided to ensure drug integrity and therapeutic effect. Avoid use if tablets are broken, broken, or incomplete.

In order to maintain a stable blood concentration of lorlatinib in the body, patients should try to take the drug at the same time every day. If you occasionally miss a dose, you should take it as soon as possible, unless it is less than 4 hours before the next dose. At this point, the patient does not need to double the dose to compensate for the omission, but rather continues to take the medication as originally planned.

In addition, it should be noted that if patients experience vomiting after taking lorlatinib, they should avoid taking additional doses and continue to take the next dose according to the original plan to prevent possible adverse reactions and risks caused by drug overdose.

In summary, lorlatinib provides a new treatment approach for patients with ALK-positive metastatic NSCLC. During use, patients should strictly abide by medical instructions, take medications correctly, and pay close attention to adverse reactions. Through scientific and rational use of medication, lorlatinib is expected to bring better therapeutic effects to patients.